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1

Pharmacological treatment of Chagas disease with benznidazole (BNZ) is effective in children in all stages, but it
is controversial in chronically infected adults. We report the pharmacokinetics and pharmacodynamics in six adult
patients with Chagas disease treated with the new BNZ formulation (ABARAX®) in doses between 2.5-5.5 mg/Kg/
day. All but one patient had plasmatic BNZ concentrations within the expected range. All patients finalised treatment
with nondetectable Trypanosoma cruzi quantitative polymerase chain reaction, which remained nondetectable at
the six month follow-up. Our data suggests parasitological responses with the new BNZ and supports the hypothesis
that treatment protocols with lower BNZ doses may be effective.
Key words: pharmacology - Chagas disease - benznidazole

Chagas disease, a zoonotic disease affecting six million people in Latin America, is caused by the haemoflagellate protozoan known as Trypanosoma cruzi (WHO
2015). Treatment for Chagas disease, developed more
than 40 years ago, is highly effective during the acute
phase of the infection and in chronically infected children (de Andrade et al. 1996, Sosa-Estani et al. 1998),
but its efficacy in the chronic stage in adults is still subject of intense controversy (Villar et al. 2014). However,
trypanocidal treatment for chronic Chagas disease has
increased in the past decade due to recommendations by
multiple national and international organizations.
Benznidazole (BNZ) is currently considered the trypanocidal drug of choice for the treatment of Chagas disease, and nifurtimox a valid alternative option. Limited
human data is available for both drugs, leading to a limited understanding of their clinical pharmacology, particularly of the mechanisms involved in the therapeutic response and the high rate of adverse drug reactions (ADRs)
(Castro et al. 2006, Hasslocher-Moreno et al. 2012).
We studied six adult patients with Chagas disease
treated with the new BNZ formulation, ABARAX®.
Chagas disease was diagnosed by means of at least two
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positive serological tests for T. cruzi (indirect immunofluorescence, enzyme immunoassay and/or indirect haemagglutination). None of the patients had received trypanocidal treatment before. All patients presented laboratory
tests within normal values and a negative pregnancy test
for women in reproductive age. During treatment, patients
were advised to follow a low fat diet, excluding histaminergic foods and alcohol. Contraception was also indicated
for women in reproductive age. Clinical laboratory tests
(haemogram, liver enzymes, and renal function tests)
were obtained at 25 and 45 ± 5 days of treatment; medical follow-up visits were planned at 35 ± 7 days. Realtime PCR for satellite and kinetoplastid DNAs of T. cruzi
(Ramírez et al. 2015) were done before treatment, at the
end of treatment, and after six months of follow-up as an
early surrogate biomarker of potential for treatment failure (Molina et al. 2014, Morillo et al. 2015, Pinazo et al.
2015). This study was approved by Bioethics Committee
of Fatala Chaben Institute on 1 August 2013; our ethics
review board does not provide protocol.
Treatment was scheduled according to current adult
treatment guidelines (MSAL 2012). Blood extractions
for therapeutic drug monitoring were done under express patient consent, but considered part of required
therapeutic measures. Plasma samples were obtained
pre and post-doses, for therapeutic drug monitoring purposes, during steady state phase of the drug (i.e., at least
after 48 h or after four half-lives from the start of the
treatment). BNZ was measured in plasma using a previously published high-performance liquid chromatography method (Marson et al. 2013). All patients consented
to the procedures and treatment.
BNZ doses ranged from 4.12-5.50 mg/Kg/day in four
patients and 2.50-2.60 mg/Kg/day in two patients (patients 1 and 2) who did not follow medical indications
and took half the prescribed dose (i.e, 100 mg bid instead
of 200 mg bid) (Table I).
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TABLE I
Clinical features of treated patients
Patient
ID

BNZ
BNZ dose treatment
(mg/kg/day) (days)

Age
(years)/gender

Place of
birth

SatDNA and
kDNA qPCRs

1

45/M

Paraguay

2.60

60

ND/ND/ND

2

33/F

Argentina

2.50

60

NQ/ND/ND

3

33/M

Argentina

5.48

23

ND/-/ND

4

29/F

Bolivia

4.12

32

ND/ND/-

5
6

21/M
31/M

Bolivia
Bolivia

4.55
4.55

60
60

NQ/ND/ND
NQ/ND/-

Adverse drug reactions
10th day: mild dermatitis
53rd day: mild myalgia in lower limbs
45th day: pruritus
24th day after EOT: cervical lymph node pain
13th day: mild dermatitis
23rd day: oral mucositis, dysgeusia, and
paresthesia in lower limbs
9th day: pruritus
26th day: liver enzymes 20 times UNL,
hypereosinophilia
Not observed
Not observed

BNZ: benznidazole; EOT: end of treatment; F: female; M: male; ND: nondetectable; NQ: nonquantifiable (time of measurement:
baseline/end of treatment/6 month of follow-up); qPCR: quantitative polymerase chain reaction; UNL: upper normal level.

Measured plasma BNZ concentrations ranged from
4.6-15.0 mg/L (Table II). Ratio of plasma BNZ concentration (mg/L)/BNZ administered dose (mg/Kg/day) showed a
narrow range of values, from 1.0-3.0 mg/L of BNZ per mg
of drug administered, except for patient 1 (Figure, Table II).
Patient 1, who took half the prescribed dose (i.e., 2.5
mg/Kg/day BID), had BNZ plasma levels higher than
those patients taking full dose. This patient was not taking any other medications, nor had any diseases or conditions known to affect BNZ pharmacokinetics. Actual
dosage was confirmed by pill counts (number of BNZ
tablets in the pill bottle was compatible with the patient
taking a reduced dose, i.e, twice the number of tablets
expected were observed in the bottle) and intensive reviewing of drug intake history with the patient.
Patient 2, who also took half the prescribed BNZ
dose, had BNZ concentrations compatible with this dosage (Table II). In spite of lower BNZ plasma levels, this
patient showed an appropriate parasitic response to BNZ
[i.e., nondetectable quantitative polymerase chain reaction (qPCR) for parasite DNA at six months follow-up].
In addition, three out of six patients [patients 2, 5,
and 6 (Table I)] had positive qPCRs for T. cruzi SatDNA
and kDNA at baseline, whereas all patients in this series
had nondetectable qPCR at the end of treatment and at
six months of follow-up for both qPCR methods. Four
patients developed ADRs during treatment and two patients had severe ADRs which required treatment discontinuation (patients 3 and 4). A relationship between
plasmatic BNZ dosage and ADRs was not observed in
this small number of cases.
Historically, medication availability has been one of
the most important health issues related to neglected diseases such as Chagas disease. BNZ was developed and
produced by Roche until 2011 when production was discontinued (Jannin & Villa 2007). BNZ production was

later taken up by the Brazilian pharmaceutical company
LAFEPE and Argentinian laboratory ELEA. The latter
developed a new BNZ formulation named ABARAX®,
which was fast-tracked by the Argentine National Food,
Drug, and Medical Technology Agency due to the urgent problem of re-establishing an adequate BNZ supply (Navarro et al. 2012). Unfortunately, emergency approval of the new formulation and the fact that there is
no stock of the original drug formulation produced by
Roche meant that no bioequivalence studies were carried out (ANMAT 2012). This situation leads to a lack
of pharmacological data on drug bioavailability to guide
dose adjustments of the new formulation.
We observed no relationship between plasma BNZ
values and occurrence of adverse events or their severity in this limited small series. This observation is in line
with previous similar studies (Pinazo et al. 2013, Salvador
et al. 2015). However, a remarkably high rate of ADRs
was observed in our patients group. All patients studied
had nondetectable T. cruzi SatDNA and kDNA qPCRs at
the end of treatment and at six months follow-up, including those who could not complete treatment due to ADRs
and those who had lower BNZ plasma levels. This observation shows probably parasitological responses to BNZ
treatment even at lower exposures and provides further
support to the hypothesis that treatment protocols with
lower BNZ doses could be effective, as suggested by previous observations in children (Altcheh et al. 2011) and
adults treated with different BNZ formulations. Moreover
in silico models, computer simulations of biological models show that a lower dose (2.5 mg/kg/d) would be enough
to achieve minimum plasma concentrations within the
proposed therapeutic BNZ range between 3-6 mg/L (Soy
et al. 2015). Lower doses may have, at least in theory, the
advantage of a lower incidence of ADRs, the primary
cause of discontinuation of drug treatment.
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TABLE II
Pharmacometric parameters of patients

Patient
ID
1a,b

Time in
BNZ treatment
(day)
53
55
60

2a

60

3c

5

4c

5

5

17

6

5

Plasma samples
(times per patient)

Sampling time
after last intake
(hours)

Plasmatic BNZ
(mg/L)

Plasmatic BNZ
(mg/L)/
BNZ daily dose
(mg/Kg)

1/1
1/2
2/1
2/2
3/1
3/2
0
1
2
0
1
2
0
1
2
0
1
2
0
1
2

1.1
2.7
1.0
2.5
1.1
3.1
0.0
1.0
2.0
0.0
1.0
2.0
0.0
1.0
2.0
0.0
1.0
2.0
0.0
1.0
2.0

8.1 ± 0.1
12.5 ± 0.6
11.6 ± 0.3
15.0 ± 0.2
11.5 ± 0.1
8.2 ± 0.1
4.6 ± 0.1
4.9 ± 0.1
5.1 ± 0.1
5.7 ± 0.5
7.1 ± 0.1
6.8 ± 0.1
7.3 ± 0.1
8.4 ± 0.1
12.0 ± 0.3
7.5 ± 0.1
8.1 ± 0.1
9.7 ± 0.3
7.1 ± 0.1
9.4 ± 0.1
9.3 ± 0.1

3.12
4.81
4.46
5.77
4.42
3.15
1.84
1.96
2.04
1.04
1.30
1.24
1.77
2.04
2.91
1.65
1.78
2.13
1.56
2.07
2.04

a: patients 1 and 2 - 2.5 and 2.6 mg/kg/day dose; b: patient 1 had two samples per day from three different days; c: patients 3 and
4 - treatment was interrupted; BNZ: benznidazole.

Ratio of plasma benznidazole (BNZ) concentration (mg/L)/BNZ administered dose (mg/Kg/d) during steady state phase. Patient 1 had
two samples per day from three different days showed a high ratio
of BNZ concentration all the times (1/1: patient 1, samples day 1;
1/2: patient 1, samples day 2; 1/3: patient 1, samples day 3). Patient 2
took half the indicated dose, her plasma drug concentration was normalised according to BNZ administered dose, and presented similar
ratio as the rest of the patients of the series (patients 3, 4, 5, and 6).

We have no clear explanation for the observed pharmacokinetic behaviour in the patient who disclosed taking half BNZ dose but had BNZ plasma levels higher than
patients treated with a full BNZ dose. Unfortunately, little
is known about what factors that may affect BNZ pharmacokinetics. Considering that the patient’s dosage was
compatible with the number of tablets left in his pill bottle
and that he was not receiving any other medications nor
had any clinical conditions that could affect BNZ elimination, we may speculate that it is possible that this patient
had a polymorphism, hitherto unknown, in the molecular
mechanisms involved in the elimination of BNZ that could
have led to accumulation to higher concentrations than expected. This is a tantalising possibility that we are currently exploring, but research in this area is significantly hampered by the lack of knowledge on absorption mechanisms,
metabolism, and elimination pathways of BNZ up to date.
This study suggests that BNZ responses continue to
be high with the currently available BNZ formulation
(ABARAX®) and provides new support to the hypothesis that treatment protocols with lower BNZ doses may
still be effective. Preliminary observations in one of our
patients suggest polymorphic behaviour in the elimination of the drug, which needs to be further explored in
clinical and basic studies.
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